Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Clinical trial NCT06617936 · RECRUITING

Trial details

NCT number: NCT06617936
Sponsor: Hua Zhang
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Non-small Cell Lung Cancer

Start date: 2024-08-27
Primary completion: 2026-09-10
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.